This inventor holds 8 USPTO granted patents and 17 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: University of California, North Carolina State University, Stefano Menegatti. Active years: 2015-2024.
Location History:
- Willow Spring, NC (US) (2015)
- Raleigh, NC (US) (2018 - 2024)
Company Filing History:
5 out of 15,988 
2 out of 1,488 
1 out of 1 Years Active: 2015-2024
Title: The Innovative Contributions of Stefano Menegatti
Introduction
Stefano Menegatti is a prominent inventor based in Raleigh, NC (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of novel drug delivery systems. With a total of 8 patents to his name, Menegatti's work focuses on enhancing the efficacy of anticancer therapies through innovative polymer-drug conjugates.
Latest Patents
One of Menegatti's latest patents involves the creation of polymer-drug conjugates for combination anticancer therapy. This patent describes pharmaceutical compositions that comprise two or more therapeutically active agents, such as anticancer agents, conjugated to biocompatible polymers. The unique aspect of these compositions is that the molar ratio of the agents and the schedules of delivery are designed to provide a synergistic therapeutic effect. The methods of making and using these pharmaceutical compositions are also detailed in the patent. In one embodiment, the compositions include topoisomerase I and topoisomerase II inhibitors that are conjugated to the same or different biocompatible polymers. The anticancer agents are covalently coupled to the polymers, allowing for targeted delivery to tumors at a molar ratio that enhances their therapeutic effect. Additionally, the agents may be coupled indirectly to the polymers via a linker.
Career Highlights
Throughout his career, Menegatti has worked with esteemed institutions such as the University of California and North Carolina State University. His research has significantly advanced the understanding of drug delivery systems and their applications in cancer therapy. His innovative approach to combining different therapeutic agents has opened new avenues for effective treatment strategies.
Collaborations
Menegatti has collaborated with notable colleagues in his field, including Samir M Mitragotri and Kathryn M Camacho. These collaborations have further enriched his research and contributed to the development of groundbreaking pharmaceutical technologies.
Conclusion
Stefano Menegatti's contributions to the field of pharmaceutical sciences are noteworthy and impactful. His innovative work on polymer-drug conjugates for anticancer therapy exemplifies the potential of combining different therapeutic agents to enhance treatment efficacy. His ongoing research continues to inspire advancements in cancer treatment methodologies.